Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details) - shares |
Sep. 30, 2024 |
Sep. 30, 2023 |
|---|---|---|
| Tyme | ||
| Anti-dilutive securities | ||
| Warrants issued to purchase common stock | 41,085 | 41,085 |
| Private Placement - December 2020 | ||
| Anti-dilutive securities | ||
| Warrants issued to purchase common stock | 282,809 | 282,809 |
| Private Placement - September 2022 | ||
| Anti-dilutive securities | ||
| Warrants issued to purchase common stock | 13,813,912 | 13,813,912 |
| First Draw of Loan Agreement | ||
| Anti-dilutive securities | ||
| Warrants issued to purchase common stock | 2,754 | 2,754 |
| Second Draw on Loan Agreement | ||
| Anti-dilutive securities | ||
| Warrants issued to purchase common stock | 1,738 | 1,738 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|